Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

November 2011

Clinical Trials, Cohort Studies, Pilot Studies

Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Chayama K, Takahashi S, Toyota J, et al. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24724. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21987462

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Alvarez GC, Gómez-Galicia D, Rodríguez-Fragoso L, et al. Ann Hepatol. 2011 Oct-Dec;10(4):458-68.

http://www.ncbi.nlm.nih.gov/pubmed/21911886

The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C. Zeuzem S, Buggisch P, Agarwal K, et al. Hepatology. 2011 Oct 17. doi: 10.1002/hep.24744. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22006408

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients. Arase Y, Suzuki Y, Suzuki F, et al. Intern Med. 2011;50(19):2083-8. Epub 2011 Oct 1.

http://www.ncbi.nlm.nih.gov/pubmed/21963723

Retrospective Chart Review to Assess the Relationship Between Depression and Sustained Virological Response From Interferon Treatment for Hepatitis C Virus. Wackernah RC, Lou M, Park SH. Clin Ther. 2011 Oct 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21982383

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.

de Knegt RJ, Bezemer G, Van Gool AR, et al. Aliment Pharmacol Ther. 2011 Oct 17. doi: 10.1111/j.1365-2036.2011.04867.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21999489

The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C. Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Eur J Gastroenterol Hepatol. 2011 Oct 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21971375

Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Amer ME, El-Sayed SZ, El-Kheir WA, et al. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):936-41.

http://www.ncbi.nlm.nih.gov/pubmed/21900788

Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Grebely J, Pham ST, Matthews GV, et al. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24754. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22031335

Basic and Applied Science, Pre-Clinical Studies

Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Antimicrob Agents Chemother. 2011 Oct;55(10):4569-74. Epub 2011 Aug 8.

http://www.ncbi.nlm.nih.gov/pubmed/21825288

An Objective Assessment of Conformational Variability in Complexes of Hepatitis C Virus Polymerase with Non-Nucleoside Inhibitors. Caillet-Saguy C, Simister PC, Bressanelli S. J Mol Biol. 2011 Oct 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22008450

Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Neumann-Haefelin C, Oniangue-Ndza C, Kuntzen T, et al. Hepatology. 2011 Oct;54(4):1157-66. doi: 10.1002/hep.24541.

http://www.ncbi.nlm.nih.gov/pubmed/22006856

Activation of chemokine and inflammatory cytokine response in HCV-infected hepatocytes depends on TLR3 sensing of HCV dsRNA intermediates. Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24763. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22030901

Redistribution of regulatory T-cells across the evolving stages of chronic hepatitis C. Ferri S, Lalanne C, Lanzoni G, et al. Dig Liver Dis. 2011 Oct;43(10):807-13.

http://www.ncbi.nlm.nih.gov/pubmed/21684822

No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. Urbánek P, Leníček M, Muchová L, et al. Ann Hepatol. 2011 Oct-Dec;10(4):445-51.

http://www.ncbi.nlm.nih.gov/pubmed/21911884

Monoclonal antibody 2-152a suppresses hepatitis C virus infection through betaine/GABA transporter-1. Satoh M, Saito M, Takano T, et al. J Infect Dis. 2011 Oct 15;204(8):1172-80.

http://www.ncbi.nlm.nih.gov/pubmed/21917889

The hepatitis C virus core protein decreases lipid droplet turnover: A mechanism for core-induced steatosis. Harris C, Herker E, Farese RV, Ott M. J Biol Chem. 2011 Oct 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21984835

HIV/HCV Coinfection

Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. Masia M, Padilla S, Robledano C, Ramos JM, Gutierrez F. BMC Infect Dis. 2011 Oct 3;11(1):265. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21967471

High FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients.

Park LS, Tate JP, Justice AC, et al. Cancer Epidemiol Biomarkers Prev. 2011 Oct 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22028407

Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients. Milazzo L, Cesari M. Expert Rev Anti Infect Ther. 2011 Oct;9(10):859-62.

http://www.ncbi.nlm.nih.gov/pubmed/21973297

High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic. Kieran J, Dillon A, Farrell G, et al. Int J STD AIDS. 2011 Oct;22(10):571-6.

http://www.ncbi.nlm.nih.gov/pubmed/21998177

Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability. Préau M, Protopopescu C, Raffi F, et al. AIDS Care. 2011 Oct 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21999644

Prevalence and Temporal Trends of Hepatitis B, Hepatitis C, and HIV/AIDS Co-infection During Pregnancy Across the Decade, 1998-2007. Salihu HM, Connell L, Salemi JL, August EM, Weldeselasse HE, Alio AP. J Womens Health (Larchmt). 2011 Oct 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22011209

Alcohol use among patients with HIV infection. Bonacini M. Ann Hepatol. 2011 Oct-Dec;10(4):502-7.

http://www.ncbi.nlm.nih.gov/pubmed/21911892

Clinical contributors to cerebral white matter integrity in HIV-infected individuals.

Gongvatana A, Cohen RA, Correia S, et al. J Neurovirol. 2011 Oct 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21965122

Epidemiology, Diagnostics, and Miscellaneous Works

Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the HALT-C trial. Everson GT, Shiffman ML, Hoefs JC, et al. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24752. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22030902

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Halfon P, Bourliere M, Ouzan D, et al. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):931-5.

http://www.ncbi.nlm.nih.gov/pubmed/21900787

Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ridruejo E, Solano A, Marciano S, et al. Ann Hepatol. 2011 Oct-Dec;10(4):452-7.

http://www.ncbi.nlm.nih.gov/pubmed/21911885

Naturally Occurring Genotype 2b/1a Hepatitis C Virus in the United States. Bhattacharya D, Accola MA, Ansari IH, Striker R, Rehrauer WM. Virol J. 2011 Oct 3;8(1):458. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21967740

From proteomic multimarker profiling to interesting proteins: thymosin-β(4) and kininogen-1 as new potential biomarkers for inflammatory hepatic lesions. Henkel C, Schwamborn K, Zimmermann HW, et al. J Cell Mol Med. 2011 Oct;15(10):2176-2188. doi: 10.1111/j.1582-4934.2010.01204.x.

http://www.ncbi.nlm.nih.gov/pubmed/21496200

Comparison of Transient Elastography and Acoustic Radiation Force Impulse for Non-Invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C. Rizzo L, Calvaruso V, Cacopardo B, et al. Am J Gastroenterol. 2011 Oct 4. doi: 10.1038/ajg.2011.341. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21971536

Upper limits of normal for alanine aminotransferase activity in the United States population. Ruhl E, Everhart JE. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24725. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21987480

Body piercing and tattoos: a survey on young adults' knowledge of the risks and practices in body art. Quaranta A, Napoli C, Fasano F, et al. BMC Public Health. 2011 Oct 7;11:774.

http://www.ncbi.nlm.nih.gov/pubmed/21981772

Impact of Fibroscan on management of chronic viral hepatitis in clinical practice. van de Putte DF, Blom R, van Soest H, et al. Ann Hepatol. 2011 Oct-Dec;10(4):469-76.

http://www.ncbi.nlm.nih.gov/pubmed/21911887

Mallory-denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Rakoski MO, Brown MB, Fontana RJ, et al. Clin Gastroenterol Hepatol. 2011 Oct;9(10):902-909.e1. Epub 2011 Jul 23.

http://www.ncbi.nlm.nih.gov/pubmed/21782771

Screening inventories to detect depression in chronic hepatitis C patients. Fábregas BC, Vitorino FD, Rocha DM, et al. Gen Hosp Psychiatry. 2011 Oct 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22001550

Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review.Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Int J Drug Policy. 2011 Oct 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22000602

Absenteeism and productivity among employees being treated for hepatitis C. Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Am J Manag Care. 2011 Oct;17(10):657-64.

http://www.ncbi.nlm.nih.gov/pubmed/21999674

Liver Cancer

Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. Marra M, Sordelli IM, Lombardi A, et al. J Transl Med. 2011 Oct 10;9(1):171. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21985599

Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. J Immigr Minor Health. 2011 Oct;13(5):842-8.

http://www.ncbi.nlm.nih.gov/pubmed/20890660

Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma. Miyatake H, Kobayashi Y, Iwasaki Y, et al. Dig Dis Sci. 2011 Oct 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21989822

Comparative Analysis of Outcome in Patients With Hepatocellular Carcinoma Exceeding the Milan Criteria Treated With Liver Transplantation Versus Partial Hepatectomy.

Canter RJ, Patel SA, Kennedy T, et al. Am J Clin Oncol. 2011 Oct;34(5):466-471.

http://www.ncbi.nlm.nih.gov/pubmed/20938319

Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. Tomoda T, Nouso K, Sakai A, et al. J Gastroenterol Hepatol. 2011 Oct 17. doi: 10.1111/j.1440-1746.2011.06948.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22004425

Up-regulation of 42 kDa Tubulin Alpha-6 Chain Fragment in Well-differentiated Hepato-cellular Carcinoma Tissues from Patients Infected with Hepatitis C Virus. Kuramitsu Y, Takashima M, Yokoyama Y, et al. Anticancer Res. 2011 Oct;31(10):3331-6.

http://www.ncbi.nlm.nih.gov/pubmed/21965743

Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Smith BD, Teshale E, Jewett A, et al. Clin Infect Dis. 2011 Oct;53(8):780-6.

http://www.ncbi.nlm.nih.gov/pubmed/21921221

Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Solomon M, Bonafede M, Pan K, et al. Dig Dis Sci. 2011 Oct;56(10):3024-31. Epub 2011 Jun 30.

http://www.ncbi.nlm.nih.gov/pubmed/21717127

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. Nkontchou G, Ziol M, Aout M, et al. J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.

http://www.ncbi.nlm.nih.gov/pubmed/21914071